Expression of antibodies in Ms-704PF CHO cells had previously been shown to result in antibodies deficient in fucose [18,24]. == Glycosylation analysis == To characterize MDX-1342 glycans, N-linked oligosaccharides were released from IgG samples (100g) by overnight incubation of the samples with 12.5mU PNGaseF (Prozyme) at 40C. activity in both B-cell malignancies and autoimmune diseases [1,2]. However, a subpopulation of patients does not respond to current therapeutic brokers [3,4], hence there remains a need for an agent with enhanced mechanisms of B-cell depletion. CD19 represents an interesting B-cell target with a number of potential advantages over CD20-directed therapies. CD19 is usually expressed throughout the developmental stages of B cells yet is not expressed on hematopoietic stem cells, T cells, or other non-lymphoid cells. In addition, CD19 is usually expressed later than CD20 through the plasmablast stage of B-cell differentiation [1]. Consequently, CD19 expression is usually relatively high in many pre-B- and immature B-lymphoblastic leukemias and B-cell ORM-10962 malignancies in which CD20 is ORM-10962 usually poorly expressed. CD19+plasmablasts may also ORM-10962 play a role in the perpetuation of autoimmune diseases [5]. The potential of CD19 as an immunotherapeutic target was recognized many years ago, but initial clinical trials with monoclonal antibodies (mAbs) to CD19 did not result in durable effects despite demonstrating responses in some patients either as a single agent or ORM-10962 in combination with other therapeutic brokers [6,7]. A number of methods have been attempted to improve the activity of CD19-directed therapy, including the use of antibodydrug conjugates [8,9] and re-direction of immune effector cells with bispecific antibodies [10,11]. Both ORM-10962 of these approaches appear to hold considerable promise for the development of novel therapies, and a recent clinical trial with a bispecific antibody targeting CD19 and CD3 confirmed that such an approach could generate significant antitumor effects at low doses [12]. There has also been recent interest in enhancing the efficacy of antibody therapeutics through increased Fc receptor binding and, consequently, increased activation of effector mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis. Fc receptor-dependent effector mechanisms have been demonstrated to be particularly important in rituximab-based lymphoma therapy [13,14]. The Fc receptor on macrophages and NK cells, FcRIIIa, has two polymorphic isoforms at residue 158, valine (Val) and GCN5 phenylalanine (Phe). Of these, the FcRIIIa-Val158 isoform shows increased binding affinity to human IgG1 antibodies resulting in increased effector function. Clinical responses to rituximab have been significantly better in patients transporting the FcRIIIa-Val158 isoform compared to the lower affinity FcRIIIa-Phe158 isoform, and this correlates with improved in vitro ADCC activity [14]. Improved binding to both polymorphic isoforms of FcRIIIa can be obtained by mutating specific amino acid residues within the Fc region of the antibody [15,16] or by modification of the N-linked carbohydrate attached to the IgG1 CH2 domain name [17,18]. Both methods have proved successful in increasing ADCC activity at lower antibody concentrations irrespective of FcRIIIa isoform. Increased activity in animal models has also been exhibited [19,20]. One of the most successful modifications to the Fc carbohydrate structure has been the removal of fucose, which results in an improved binding conversation with the FcRIIIa carbohydrate [21]. A small proportion of native IgG is usually nonfucosylated, thus the generation of immune reactions to the glycoengineered antibody is usually unlikely. Moreover, the improved ADCC activity generated with nonfucosylated antibodies may allow enhanced anticancer activity without the immunogenic risk of amino acid substitutions in the human Fc structure. In this statement, we describe the activity of a fully human antibody to CD19 that has been produced in nonfucosylated form to enhance Fc receptor-mediated effector function. This mAb is currently in phase 1 trials for the treatment of chronic lymphocytic leukemia and rheumatoid arthritis. == Materials and methods == == Antibody generation == Transgenic mice expressing human immunoglobulin genes [22] were immunized with CD19-expressing cells and purified soluble recombinant CD19 extracellular domain name expressed in CHO cells. Human mAbs were generated using standard hybridoma techniques and screened in the beginning for their ability to bind to CD19-transfected CHO cells by circulation cytometry, using untransfected cells as controls. After subsequent testing, genes from your lead hybridoma antibody were cloned, sequenced, and re-expressed in CHO cells by standard techniques to produce parental anti-CD19.